GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (LSE:LEL) » Definitions » Cyclically Adjusted PB Ratio

Eli Lilly and Co (LSE:LEL) Cyclically Adjusted PB Ratio : (As of May. 01, 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 13.64 22.03 28.80 46.99

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.80 26.87 36.73 42.35 46.99

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=9.628/129.4194*129.4194
=9.628

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201403 16.391 99.695 21.278
201406 16.074 100.560 20.687
201409 15.793 100.428 20.352
201412 13.741 99.070 17.951
201503 13.336 99.621 17.325
201506 13.113 100.684 16.855
201509 13.605 100.392 17.539
201512 13.024 99.792 16.891
201603 13.416 100.470 17.282
201606 13.083 101.688 16.651
201609 13.934 101.861 17.704
201612 12.521 101.863 15.908
201703 12.541 102.862 15.779
201706 12.604 103.349 15.783
201709 13.309 104.136 16.540
201712 10.362 104.011 12.893
201803 12.985 105.290 15.961
201806 10.328 106.317 12.572
201809 11.688 106.507 14.202
201812 8.785 105.998 10.726
201903 2.217 107.251 2.675
201906 2.485 108.070 2.976
201909 3.023 108.329 3.612
201912 2.330 108.420 2.781
202003 2.752 108.902 3.270
202006 3.658 108.767 4.353
202009 4.314 109.815 5.084
202012 5.043 109.897 5.939
202103 6.166 111.754 7.141
202106 5.760 114.631 6.503
202109 6.933 115.734 7.753
202112 8.026 117.630 8.830
202203 8.340 121.301 8.898
202206 7.638 125.017 7.907
202209 9.001 125.227 9.302
202212 9.519 125.222 9.838
202303 10.002 127.348 10.165
202306 9.889 128.729 9.942
202309 10.029 129.860 9.995
202312 9.628 129.419 9.628

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (LSE:LEL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (LSE:LEL) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (LSE:LEL) Headlines

No Headlines